Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.
Here’s our summary of key points from selected presentations at the 2018 European meeting of ISMPP.
Based on our experience, we believe that ORCID can make medical publishing faster and more transparent.
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process
Personal commentary from Richard Smith, chair of Open Pharma
Since the sudden disappearance of his list of so-called predatory journals in January 2017, Jeffrey Beall has maintained silence on the subject for which he has become famous. In a recent webinar, a recording of which can be accessed here, this silence was broken. His emergence back into the public eye is part of a … Continue reading Predatory journals are back in the firing line